Ownership: Minority, woman
Self reported impact: Potential to do so in the next 12 months.
One sentence summary:
Sonavi Labs created Feelix, an Ai-enabled platform that includes digital screening devices, supportive software and an integrated cloud system to aid in the detection and management of diseases.
Description of impact:
Asthma and COPD are two of the world’s most common and pervasive chronic conditions. Pneumonia and tuberculosis are two of the world’s most deadly acute diseases. The Feelix platform is designed to evolve the standards of disease management and detection by allowing the ability to screen for abnormalities using hand-held, digital acoustic devices, embedded with advanced analytics but simple enough for anyone to use. The Feelix devices incorporate adaptive noise suppression and other advanced features, like Bluetooth connectivity, on-board storage and a proprietary classification algorithm to aid in the detection and management of chronic and acute conditions such as asthma and COPD.
With the Feelix device, patients in rural and suburban communities can remotely manage chronic illness while having more consistent and effective engagement with care teams from any location. We believe that chronic disease exacerbations can be predicted, and potentially avoided by deploying the Feelix platform’s advanced machine learning capabilities. We have already begun working with Hopkins Hospital in Baltimore to study minority asthmatic patients, and the INOVA hospital in Virginia to monitor patients recovering from lung transplants.
We are working to deploy the Feelix platform to patients who frequently visit the ER through pilots we are launching over the next year. Within five years, we anticipate millions of patients around the world using Feelix devices to help manage their health.